

## Index

*Note:* Page numbers of article titles are in **boldface** type.

### A

- Acetic acid, in exhaled breath condensate, 593
- Acid reflux, exhaled breath condensate pH assays in, 603–604
- Acidity, airway. *See* Exhaled breath condensate, pH assays of.
- Acute respiratory distress syndrome, exhaled breath condensate pH assays in, 603, 605
- Adenosine 5'-monophosphate challenge testing, 642–643
- ADRβ2* gene. *See* β2-Adrenergic receptor gene.
- β2-Adrenergic agonists  
controversy over, 666–667  
pharmacogenetics of  
    in acute short-acting therapy, 669, 671–672, 678–679  
    in chronic regular short-acting therapy, 672–676  
    in long-acting therapy, 676–679
- β2-Adrenergic receptor gene, **665–684**  
    β2-adrenergic agonist controversy and, 666–667  
    pharmacogenetics of, 667–679  
        at molecular level, 668–670  
        in acute short-acting beta-agonist therapy, 669, 671–672, 678–679  
        in chronic regular short-acting beta-agonist therapy, 672–676  
        in long-acting beta-agonist therapy, 676–679  
    structure and, 667–668
- Airflow modeling, for exhaled nitric oxide measurement, 574
- Albuterol, pharmacogenetics of  
    in acute therapy, 669, 671–672, 678–679  
    in chronic regular therapy, 672–676
- ALFA monitor, for exhaled breath condensate monitoring, 602–603
- American Thoracic Society, exhaled nitric oxide measurement standards of, 574–575
- Ammonia, in exhaled breath condensate, 593, 601
- Anaconda system, for exhaled breath condensate collection, 592
- Asthma  
    β2-adrenergic receptor gene in, **665–684**  
    bronchoprovocation testing in, **633–649**  
    components of, 577–578  
    eosinophilic  
        biomarkers for, 624–627  
        exhaled nitric oxide in, 574–575  
        neutrophilic, biomarkers for, 627–628  
        paucigranulocytic, biomarkers for, 628  
        phenotypes of, 623–624  
        relapse of, sputum eosinophilia predicting, 616–618  
    remodeling in, biomarkers for, 628–629  
    severity of  
        sputum eosinophilia with, 609–612  
        urinary leukotriene E<sub>4</sub> levels and, 656–659  
    treatment of. *See also* Glucocorticoids.  
        sputum eosinophilia and, 618–620  
        urinary leukotriene E<sub>4</sub> levels and, 659–660
- Asthma biomarkers  
    exhaled nitric oxide, **571–586**  
    in bronchoalveolar lavage fluid, **623–632**  
    in exhaled breath condensate, **587–596, 597–606**  
    in sputum, **607–622**  
    tissue based, **623–632**  
    urinary leukotriene E<sub>4</sub>, **651–664**

**B**

- Beclomethasone, sputum eosinophilia and, 615
- Beta-Adrenergic Response by Genotype Trial, 674–676, 678–679
- Beta-Agonists Study (BAGS), 666, 674, 678–679
- Biomarkers, asthma. *See* Asthma biomarkers.
- Breath condensate, exhaled. *See* Exhaled breath condensate.
- Bronchiolitis obliterans, exhaled nitric oxide measurement in, 581
- Bronchoalveolar lavage fluid, biomarkers in, **623–632**  
 in eosinophilic asthma, 624–627  
 in neutrophilic asthma, 627–628  
 in paucigranulocytic asthma, 628  
 in remodeling, 628–629
- Bronchohyperresponsiveness, **633–649**  
 biomarker levels and, 636–638  
 bronchoprovocation challenges in applications of, 633–634  
 direct versus indirect, 640–643  
 genetic component of, 634–635  
 permanent components of, 635–636  
 therapies modifying, 639–640  
 transient components of, 635–636
- Budesonide, sputum eosinophils and, 613–614

**C**

- Carbon dioxide, as artifact, in exhaled breath condensate pH assays, 598–599
- Chemokines, in asthma, eosinophilic, 625–626
- Childhood Asthma Management Program, 671
- Chloride, in exhaled breath condensate, 593
- Chronic obstructive pulmonary disease  
 exhaled breath condensate pH assays in, 603, 605  
 exhaled nitric oxide measurement in, 579–580  
 sputum eosinophilia in, 609
- Constitutive nitric oxide synthase, 572
- Corticosteroids. *See* Glucocorticoids.
- Cysteinyl leukotriene, marker for, urinary leukotriene E<sub>4</sub> as, **651–664**

## Cystic fibrosis

- exhaled breath condensate pH assays in, 603  
 exhaled nitric oxide measurement in, 580

**E**

- ECoScreen systems, for exhaled breath condensate collection, 592
- Endotracheal intubation, exhaled breath condensate monitoring in, 602–603
- Enzyme immunoassays, for urinary leukotriene E<sub>4</sub>, 651–652
- Eosinophilia, sputum, **607–622**  
 asthma management and, 618–620  
 asthma severity and, 609–612  
 diagnostic use of, 608–609  
 glucocorticoid response and, 614–616  
 inhaled glucocorticoid effects on, 613–614  
 relapse prediction and, 616–618
- Eosinophilic asthma  
 biomarkers for, 624–627  
 exhaled nitric oxide in, 574–575
- Eotaxins, in asthma, eosinophilic, 625–626
- European Respiratory Society, exhaled nitric oxide measurement standards of, 574–575
- Exercise challenge testing, 641–642
- Exhaled breath condensate, **587–596**  
 biomarkers in  
 anatomic source of, 600–601  
 categories of, 591–596  
 source of, 587–588  
 volatile versus nonvolatile, 592–596  
 collection of, 590–591  
 dilution of, 589  
 lack of gold standards for comparison with, 590  
 oropharyngeal contribution to, 588–589  
 particle size of, 588  
 pH assays of, **597–606**  
 carbon dioxide artifact in, 598–599  
 determinants of, 600–601  
 in acid reflux, 603–604  
 in intubated patients, 602–603  
 in spontaneously breathing subjects, 604–605  
 normal values in, 600  
 technical issues in, 599–600  
 utility of, 602–605  
 validation of, 599–600

- validation of results, 590  
versus sputum eosinophilia, 608–609
- Exhaled nitric oxide, **571–586**, **587–596**  
biology of, 571–573  
factors affecting, 575–577  
generation of, 572  
glucocorticoid effects on, 576–577  
in asthma, 577–579  
in bronchiolitis obliterans, 581  
in bronchohyperresponsiveness, 638  
in chronic obstructive pulmonary disease, 579–580  
in cystic fibrosis, 580  
in eosinophilic inflammation, 575–576  
in interstitial lung disease, 580  
in primary ciliary dyskinesia, 581  
measurement of, 573–575  
normal values for, 574–575  
results interpretation for, 573–575
- F**
- 
- FE<sub>NO</sub>. *See* Exhaled nitric oxide.
- Fenoterol, 666
- Fluticasone, sputum eosinophilia and, 613, 615
- Formic acid, in exhaled breath condensate, 593
- Formoterol, pharmacogenetics of, 676–679
- G**
- 
- Gastroesophageal reflux, exhaled breath condensate pH assays in, 603–605
- Genetic factors  
in  $\beta$ 2-adrenergic agonist response, **665–684**  
in bronchohyperresponsiveness, 634–635  
in urinary leukotriene E<sub>4</sub> levels, 652
- Genetics of Asthma in Latino Americans study, 671–672
- Glucocorticoids  
bronchohyperresponsiveness and, 639–640  
response to  
exhaled nitric oxide measurements for, 576–577  
sputum eosinophilia and, 614–616  
sputum eosinophils and, 613–616  
urinary leukotriene E<sub>4</sub> levels and, 653
- Glycoproteins, in asthma, with subepithelial basement membrane remodeling, 628

**H**

- 
- Heme proteins, nitric oxide synthase interactions with, 573
- Histamine challenge testing, 640–641
- 15-Hydroxyeicosatetraenoic acid, in asthma, eosinophilic, 626–627
- Hypertonic saline challenge testing, 642

**I**

- 
- Immunoglobulin E, elevated, in bronchohyperresponsiveness, 634–635
- Immunomodulatory therapy, bronchohyperresponsiveness and, 639–640
- Inducible nitric oxide synthase, 572
- Interferon(s), in bronchohyperresponsiveness, 637–638
- Interleukin(s)  
in asthma  
eosinophilic, 625–627  
neutrophilic, 627  
in bronchohyperresponsiveness, 635, 637–639
- Interstitial lung disease, exhaled nitric oxide measurement in, 580

**L**

- 
- Leukotrienes  
cysteinyl, 651  
in eosinophilic asthma, 626  
in neutrophilic asthma, 627
- Long Acting Beta Agonist Response by Genotype study, 678
- Lung, interstitial disease of, exhaled nitric oxide measurement in, 580

**M**

- 
- Mast cells, in asthma, with subepithelial basement membrane remodeling, 629
- Matrix metalloproteinases, in asthma, neutrophilic, 627–628
- Methacholine challenge testing, 640–641

**N**

- 
- National Institutes of Health Asthma Clinical Research Network: Beta-Agonists Study (BAGS), 666, 674

Neutrophilic asthma, biomarkers for, 627–628

Nitrate, in exhaled breath condensate, 593

Nitric oxide, exhaled. *See* Exhaled nitric oxide.

Nitric oxide synthase, 572

Nitrite, in exhaled breath condensate, 593

Nitrosylation, nitric oxide synthase in, 573

## O

Omalizumab, bronchohyperresponsiveness and, 639

## P

Paucigranulocytic asthma, biomarkers for, 628

pH, of exhaled breath condensate, 594–595, **597–606**

Pharmacogenetics, of  $\beta_2$ -adrenergic receptor gene, 667–679  
 at molecular level, 668–670  
 in acute short-acting beta-agonist therapy, 669, 671–672, 678–679  
 in chronic regular short-acting beta-agonist therapy, 672–676  
 in long-acting beta-agonist therapy, 676–679  
 structure and, 668–670

Primary ciliary dyskinesia, exhaled nitric oxide measurement in, 581

## R

Reactive nitrogen species, nitric oxide synthase involvement in, 573

Reflux, acid, exhaled breath condensate pH assays in, 603–605

Remodeling, biomarkers for, 628

Respiratory syncytial virus infections, exhaled breath condensate pH assays in, 603

RTube, for exhaled breath condensate collection, 592

## S

Saline challenge testing, 642

Saliva, exhaled breath condensate contamination with, 588–589

Salmeterol  
 pharmacogenetics of, 676–679  
 sputum eosinophils and, 613

Salmeterol  $\pm$  Inhaled Corticosteroid Trial, 676–678

Salmeterol or Corticosteroids Trial, 676–678

Sputum, eosinophilia in, **607–622**  
 asthma management and, 618–620  
 asthma severity and, 609–612  
 diagnostic use of, 608–609  
 glucocorticoid response and, 614–616  
 inhaled glucocorticoid effects on, 613–614  
 relapse prediction and, 616–618

Subepithelial basement membrane, remodeling of, biomarkers for, 628–629

## T

Tenascin, in asthma, with subepithelial basement membrane remodeling, 628

Transforming growth factor- $\beta$ , in asthma, with subepithelial basement membrane remodeling, 628

Tumor necrosis factor- $\alpha$ , in bronchohyperresponsiveness, 637–638

TurboDeccs, for exhaled breath condensate collection, 592

## U

Urinary leukotriene E<sub>4</sub>, **651–664**  
 age differences in, 652  
 as asthma incidence and severity marker, 656–659  
 as cysteinyl leukotriene disease pathogenesis indicator, 653–656  
 as medication susceptibility marker, 659–660  
 genetic factors in, 652  
 measurement of, 651–652  
 modifiers of, 652–653

## Z

Zileuton, urinary leukotriene E<sub>4</sub> levels and, 653